OR WAIT 15 SECS
The acquisition will expand Nestlé’s portfolio with access to Aimmune’s Palforzia, the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reactions to peanuts in children.
Nestlé Health Science, a nutritional science company, announced on Aug. 31, 2020 that it is acquiring Aimmune Therapeutics, a biopharmaceutical company focused on commercializing treatments for life-threatening food allergies, for approximately $2.6 billion.
Under the terms of the agreement, Nestlé will acquire all shares of Aimmune common stock for $34.50 per share in cash, according to a Nestlé press release. The deal is expected to close in the fourth quarter of 2020.
The acquisition will expand Nestlé’s portfolio with access to Aimmune’s Palforzia, the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reactions to peanuts in children, the press release said.
"This transaction brings together Nestlé's nutritional science leadership with one of the most innovative companies in food allergy treatment," said Nestlé Health Science CEO Greg Behar in the press release. "Together we will be able to offer a wide range of solutions that can transform the lives of people suffering from food allergies around the world."
"The agreement with Nestlé Health Science recognizes the value created by years of commitment and dedication to our mission by the team at Aimmune. Delivering Palforzia, the world's first treatment for food allergy, has been a game-changing proposition in the bio-pharmaceutical industry and is transformative for the lives of millions of people living with potentially life-threatening peanut allergy," added Jayson Dallas, MD, president and CEO of Aimmune, in the press release. "This acquisition ensures a level of support for Palforzia and our pipeline that will further enhance their potential for patients around the world living with food allergies."